A vaccine against S. pyogenes: design and experimental immune response.
Streptococcus pyogenes causes severe invasive infections: the post-streptococcal sequelae of acute rheumatic fever (RF) and rheumatic heart disease (RHD), acute glomerulonephritis, and uncomplicated pharyngitis and pyoderma. Efforts to produce a vaccine against S. pyogenes began several decades ago, and different models have been proposed. Here, we describe the methodology used in the development of a new vaccine model, consisting of both T and B protective epitopes constructed as synthetic peptides and recombinant proteins. Two adjuvants were tested in an experimental inbred mouse model: a classical Freund's adjuvant and a new adjuvant (AFCo1) that induces mucosal immune responses and is obtained by calcium precipitation of a proteoliposome derived from the outer membrane of Neisseria meningitides B. The StreptInCor vaccine epitope co-administrated with AFCo1 adjuvant induced mucosal (IgA) and systemic (IgG) antibodies as preferential Th1-mediated immune responses. No autoimmune reactions were observed, suggesting that the vaccine epitope is safe.
Guilherme
L
L
Heart Institute (InCor), School of Medicine, University of São Paulo, Brazil. luizagui@usp.br
Postol
E
E
Freschi de Barros
S
S
Higa
F
F
Alencar
R
R
Lastre
M
M
Zayas
C
C
Puschel
C R
CR
Silva
W R
WR
Sa-Rocha
L C
LC
Sa-Rocha
V M
VM
Pérez
O
O
Kalil
J
J
D000595:Amino Acid Sequence; D000818:Animals; D015195:Drug Design; D005260:Female; D018928:Immunity, Mucosal / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D022541:Streptococcal Vaccines / Q000008:administration & dosage / Q000138:chemical synthesis / Q000276:immunology*; D013297:Streptococcus pyogenes / Q000187:drug effects / Q000276:immunology*
D022541:Streptococcal Vaccines